Caesar Belbel compensation by year
Alaunos Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2016 | FY2017 | FY2018 |
|---|---|---|---|
| Salary | $375,000 | $375,000 | $71,513 |
| Bonus | $262,500 | $328,125 | $47,260 |
| Stock awards | $504,773 | $360,180 | $0 |
| Option awards | $0 | $0 | $0 |
| Non-equity incentive | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $2,713 | $2,745 | $708,966 |
| Total | $1,144,986 | $1,066,050 | $827,739 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Alaunos Therapeutics, Inc. DEF 14A filed April 29, 2019, accession 0001193125-19-125377, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Alaunos Therapeutics, Inc. filed document, accession 0001193125-19-125377. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2019.
Alaunos Therapeutics’s named executive officers, FY2018
as the company reported each| Named executive officer | Role | FY2018 total |
|---|---|---|
| Laurence Cooper | Chief Executive Officer | $1,589,239 |
| Robert Hadfield | Executive Vice President, General Counsel and Secretary | $836,091 |
| Caesar Belbel · this page | Former Executive Vice President, Chief Legal Officer and Secretary | $827,739 |
| David Mauney | President | $608,756 |
| Kevin Lafond | Sr. Vice President – Finance, Chief Accounting Officer and Treasurer | $398,998 |
The full Alaunos Therapeutics compensation record
free company briefThis page is one person within Alaunos Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Alaunos Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Alaunos Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.